First Wave BioPharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James R. Sapirstein
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 Yamato Road Boca Raton FL United States of America 33431
- IPO Date
- Oct 11, 2016
- CIK
- 0001604191
- Website
- firstwavebio.com
- Similar Companies
- Business
- First Wave BioPharma, Inc. (Nasdaq: FWBI) is a clinical-stage biopharmaceutical company focused on developing targeted, non-systemic oral therapies for gastrointestinal diseases, including celiac disease, gastroparesis, exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients, and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; its core pipeline comprises latiglutenase, a Phase 3-ready oral biotherapeutic of gluten-specific recombinant proteases to degrade gluten and alleviate symptoms in celiac patients; capeserod, a selective 5-HT4 receptor partial agonist for GI motility disorders like gastroparesis; and adrulipase (formerly MS1819), a recombinant lipase enzyme to aid fat and nutrient digestion in exocrine pancreatic insufficiency. Founded in 2014 and headquartered in Boca Raton, Florida, with scientific operations in Langlade, France, the company formerly operated as AzurRx BioPharma, Inc. until renaming to First Wave BioPharma in September 2021. In March 2024, it completed an all-stock business combination with ImmunogenX, Inc., adding the Phase 3-ready latiglutenase program and appointing Jack Syage, Ph.D., as President and Chief Operating Officer while pursuing a strategic U.S. commercial license with a global pharmaceutical partner and institutional financing; in May 2024, it rebranded to Entero Therapeutics, Inc. (Nasdaq: ENTO) to emphasize its GI focus ahead of initiating latiglutenase Phase 3 trials in early 2025.
CORRECTION: Fold Rolls Out New Bitcoin Rewards Credit Card
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock?
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Why Is First Wave BioPharma (FWBI) Stock Up Today?
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
First Wave BioPharma to Participate In ‘Fireside Chat' at the 36th Annual Roth Conference
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
First Wave BioPharma to Present at the DealFlow MicroCap Conference
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
Why Is First Wave Biopharma (FWBI) Stock Up 148% Today?
First Wave BioPharma's stock more than doubles after deal to sell its IBD treatment
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program